DrugMapper


InChI Key	PVHLMTREZMEJCG-GDTLVBQBSA-N
Smile	CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)O
InChI	InChI=1S/C41H62N12O11/c1-5-22(4)33(38(61)50-29(17-24-19-45-20-47-24)39(62)53-15-7-9-30(53)40(63)64)52-36(59)28(16-23-10-12-25(54)13-11-23)49-37(60)32(21(2)3)51-35(58)27(8-6-14-46-41(43)44)48-34(57)26(42)18-31(55)56/h10-13,19-22,26-30,32-33,54H,5-9,14-18,42H2,1-4H3,(H,45,47)(H,48,57)(H,49,60)(H,50,61)(H,51,58)(H,52,59)(H,55,56)(H,63,64)(H4,43,44,46)/t22-,26-,27-,28-,29-,30-,32-,33-/m0/s1

Mesh Heading	Maximum Phase	Reference
Autonomic Nervous System Diseases; Hypotension; Hypotension, Orthostatic; Multiple System Atrophy; Nervous System Diseases; Primary Dysautonomias; Pure Autonomic Failure; Shy-Drager Syndrome	Early Phase 1	ClinicalTrials
Lymphopenia; Neutropenia; Thrombocytopenia	Phase 2	ClinicalTrials
Graft vs Host Disease	Phase 2	ClinicalTrials
Cognitive Dysfunction; Heart Failure	Phase 2	ClinicalTrials
Insulin Resistance; Metabolic Syndrome	Phase 1	ClinicalTrials
Myelodysplastic Syndromes; Preleukemia; Syndrome; Thrombocytopenia	Phase 1	ClinicalTrials
Graft vs Host Disease	Phase 2	ClinicalTrials
Hodgkin Disease; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms, Plasma Cell	Phase 2	ClinicalTrials
Hypertension; Obesity	Early Phase 1	ClinicalTrials
Essential Hypertension; Hypertension	Phase 1	ClinicalTrials
Congenital Abnormalities	Phase 1	ClinicalTrials
Obesity	Early Phase 1	ClinicalTrials
Metabolic Diseases; Neoplasms	Phase 2	ClinicalTrials
Cognitive Dysfunction	Phase 2	ClinicalTrials

TXA127


Active Pharmaceutical Ingredients (APIs) Scaffolds	Exact Similarity SubStructure	Threshold (%) >= 70